Fig. 3.

Anti-CD133 CAR-T cells exhibit dramatic antitumor efficacy ex vivo. a BGC-823 cells were treated with cisplatin for 48 h, and the CD133⁺ cells were isolated via flow cytometry and then incubated with anti-CD133 CAR-T cells at the indicated effector-to-target ratios. Cytotoxicity assays evaluated the cytotoxicity of T cells. The concentrations of IL-2 b, IFN-γ c, GM-CSF d, and TNFα e released by anti-CD133 CAR-T cells after coculture with normal and CD133⁺ BGC-823 cells overnight at an E/T ratio of 1:1 were shown. Data represent means ± SD. n = 3 samples. ***p < 0.001. f, g Canonical T cell markers were detected by flow cytometry at a recommended E: T ratio of 1:1 after coculturing anti-CD133 CAR-T cells with target cells. A two-way ANOVA analysis with Tukey’s post hoc test was performed to evaluate the statistical significance